Betta Pharmaceuticals' stock price plummeted by 20% to its daily limit, EyePoint's US-listed shares fell 67% overnight, and the Phase III clinical trial of voronib for wAMD failed. Betta Pharmaceuticals holds the Greater China rights to the product.

2026-08-18

Betta Pharmaceuticals' stock price plummeted by 20% to its daily limit, EyePoint's US-listed shares fell 67% overnight, and the Phase III clinical trial of voronib for wAMD failed. Betta Pharmaceuticals holds the Greater China rights to the product.